You just read:

eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination Trial to Evaluate eFFECTOR's Tomivosertib (eFT508) with KEYTRUDA® (pembrolizumab) for Metastatic Triple Negative Breast Cancer

News provided by

eFFECTOR Therapeutics, Inc.

Oct 16, 2018, 08:00 ET